Unusual RNA binding of FUS RRM studied by molecular dynamics simulation and enhanced sampling method.

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobe degeneration (FTLD) are two inter-related intractable diseases of motor neuron degeneration. Fused in Sarcoma (FUS) is found in cytoplasmic accumulation of ALS and FTLD patients, which readily link the protein with the diseases. The RNA recognition motif (RRM) of FUS has the canonical α-β folds along with an unusual lysine-rich loop (KK-loop) between α1 and β2. This KK-loop is highly conserved among FET family proteins. Another contrasting feature of FUS RRM is the absence of critical binding residues, which are otherwise highly conserved in canonical RRMs. These residues in FUS RRM are Thr286, Glu336, Thr338 and Ser367, which are substitutions of lysine, phenylalanine, phenylalanine and lysine, respectively, in other RRMs. Considering the importance of FUS in RNA regulation and metabolism, and its implication in ALS and FTLD, it is important to elucidate the underlying molecular mechanism behind RNA recognition. In this study, we have performed Molecular Dynamics simulation with enhanced sampling to understand the conformational dynamics of non-canonical FUS RRM and its binding with RNA. We studied two sets of mutations, one with alanine mutation of KK-loop and another with KK-loop mutations along with critical binding residues mutated to their canonical form. We find that concerted movement of KK-loop and β2β3-loop facilitates the folding of the partner RNA, indicating an induced-fit mechanism of RNA binding. Flexibility of the RRM is highly restricted upon mutating the lysine residues of the KK-loop, resulting in weaker binding with the RNA. Our results also suggest that absence of the canonical residues in FUS RRM along with the KK-loop is equally important in regulating its binding dynamics. This study provides a significant structural insight into the binding of FUS-RRM with its cognate RNA, which may further help in designing potential drugs targeting non-canonical RNA recognition.